HSBC Holdings
VNDA icon

HSBC Holdings’s Vanda Pharmaceuticals VNDA Stock Holding History

HSBC Holdings’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$579K Buy
94,988
+56,133
+144% +$367K ﹤0.01% 2208
2026
Q1 		$261K Buy
38,855
+3,144
+9% +$24.2K ﹤0.01% 2509
2025
Q4 		$321K Sell
35,711
-35,535
-50% -$196K ﹤0.01% 2509
2025
Q3 		$354K Buy
71,246
+4,692
+7% +$21.7K ﹤0.01% 2269
2025
Q2 		$319K Buy
66,554
+9,960
+18% +$43.6K ﹤0.01% 2401
2025
Q1 		$259K Buy
56,594
+8,545
+18% +$39.8K ﹤0.01% 2463
2024
Q4 		$229K Buy
48,049
+21,584
+82% +$104K ﹤0.01% 2646
2024
Q3 		$124K Buy
+26,465
New +$142K ﹤0.01% 2758
2024
Q1 		– Sell
-29,207
Closed -$123K – 3251
2023
Q4 		$123K Buy
+29,207
New +$118K ﹤0.01% 2564
2023
Q1 		– Sell
-10,548
Closed -$77.6K – 3071
2022
Q4 		$77.6K Buy
+10,548
New +$103K ﹤0.01% 2935
2022
Q3 		– Sell
-12,201
Closed -$132K – 3292
2022
Q2 		$132K Sell
12,201
-1,188
-9% -$12.3K ﹤0.01% 2987
2022
Q1 		$153K Buy
+13,389
New +$176K ﹤0.01% 3047

Other funds holding VNDA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HSBC Holdings's VNDA Position: Q2 2026 in Review

HSBC Holdings increased its Vanda Pharmaceuticals (VNDA) stake by 144% in Q2 2026, buying an estimated $367K and bringing the position to 94,988 shares worth $579K. The position accounts for ﹤0.01% of the portfolio, ranked #2208.

HSBC Holdings first reported a position in VNDA in Q1 2022 and has held it in 12 quarters since. 172 funds tracked by Wall St. Rank hold VNDA as of Q2 2026.

  • HSBC Holdings held 94,988 shares of Vanda Pharmaceuticals worth $579K as of Q2 2026.
  • HSBC Holdings bought 56,133 Vanda Pharmaceuticals shares in Q2 2026, an estimated $367K.
  • Vanda Pharmaceuticals made up ﹤0.01% of HSBC Holdings's portfolio in Q2 2026, its #2208 holding.
  • HSBC Holdings first reported a position in Vanda Pharmaceuticals in Q1 2022 and has held it in 12 quarters since.
  • 172 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2026.

Based on HSBC Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.